EFFICACY AND SAFETY OF BARICITINIB IN MTX-IR PATIENTS WITH RHEUMATOID ARTHRITIS: 52 WEEK RESULTS FROM A PHASE 3 STUDY (RA-BALANCE)

被引：11

作者：

Li, Z. ^{[1
,10
]}

Hu, J. ^{[2
]}

Bao, C. ^{[3
]}

Li, X. ^{[4
,5
]}

Xu, J. ^{[6
,9
]}

Spindler, A. ^{[7
]}

Zhang, X. ^{[8
]}

Xu, J. ^{[6
,9
]}

Li, Z. ^{[1
,10
]}

Wang, G. ^{[11
]}

Sun, J. ^{[12
]}

Ji, F. ^{[12
]}

Tao, H. ^{[12
]}

Zhan, L. ^{[12
]}

Rooney, T. ^{[13
]}

Zerbini, C. ^{[14
]}

机构：

[1] Peking Univ, Peoples Hosp, Beijing, Peoples R China

[2] Pingxiang Peoples Hosp, Pingxiang, Peoples R China

[3] SH Jiaotong Univ, Renji Hosp, Shanghai, Peoples R China

[4] Shandong Univ, Qilu Hosp, Jinan, Shandong, Peoples R China

[5] Anhui Prov Hosp, Hefei, Anhui, Peoples R China

[6] AnHui Med Univ, Affiliate Hosp 1, Hefei, Anhui, Peoples R China

[7] Ctr Med Privado Reumatol, San Miguel De Tucuman, Argentina

[8] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China

[9] Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China

[10] Bengbu Med C, Affiliated Hosp 1, Bengbu, Anhui, Peoples R China

[11] China Japan Friendship Hosp, Beijing, Peoples R China

[12] Eli Lilly & Co, Shanghai, Peoples R China

[13] Eli Lilly & Co, Indianapolis, IN 46285 USA

[14] Ctr Paulista Invest Clin, Sao Paulo, Brazil

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷

关键词：

D O I：

10.1136/annrheumdis-2018-eular.1983

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SAT0218

引用

页码：969 / 970

页数：2

共 50 条

[1] Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
Yue Yang
Xing-Fu Li
Xiao Zhang
Chun-De Bao
Jian-Kang Hu
Jian-Hua Xu
Xiang-Pei Li
Jian Xu
Dong-Yi He
Zhi-Jun Li
Guo-Chun Wang
Han-Jun Wu
Fei Ji
Lu-Jing Zhan
Cristiano A. F. Zerbini
Zhan-Guo Li
Rheumatology and Therapy, 2020, 7 : 851 - 866
[2] Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
Yang, Yue
Li, Xing-Fu
Zhang, Xiao
Bao, Chun-De
Hu, Jian-Kang
Xu, Jian-Hua
Li, Xiang-Pei
Xu, Jian
He, Dong-Yi
Li, Zhi-Jun
Wang, Guo-Chun
Wu, Han-Jun
Ji, Fei
Zhan, Lu-Jing
Zerbini, Cristiano A. F.
Li, Zhan-Guo
RHEUMATOLOGY AND THERAPY, 2020, 7 (04) : 851 - 866
[3] Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE
Li, Zhan-Guo
Hu, Jian-Kang
Li, Xiang-Pei
Yang, Yue
Li, Xing-Fu
Xu, Jian-Hua
Zhang, Xiao
Xu, Jian
Bao, Chun-De
He, Dong-Yi
Li, Zhi-Jun
Wang, Guo-Chun
Zuo, Xiao-Xia
Liu, Yi
Xiao, Zheng-Yu
Chen, Jin-Wei
Xin, Xia-Fei
Li, Jing-Yang
Jiang, Lin-Di
Liu, Meng-Ru
Ji, Fei
Li, Chen-Ge
ADVANCES IN THERAPY, 2021, 38 (01) : 772 - 781
[4] Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE
Zhan-Guo Li
Jian-Kang Hu
Xiang-Pei Li
Yue Yang
Xing-Fu Li
Jian-Hua Xu
Xiao Zhang
Jian Xu
Chun-De Bao
Dong-Yi He
Zhi-Jun Li
Guo-Chun Wang
Xiao-Xia Zuo
Yi Liu
Zheng-Yu Xiao
Jin-Wei Chen
Xia-Fei Xin
Jing-Yang Li
Lin-Di Jiang
Meng-Ru Liu
Fei Ji
Chen-Ge Li
Advances in Therapy, 2021, 38 : 772 - 781
[5] Efficacy and Safety of Baricitinib in Japanese Rheumatoid Arthritis Patients during a 52 Week Extension Phase.
Tanaka, Yoshiya
Emoto, Kahaku
Cai, Zhihong
Schlichting, Douglas E.
Rooney, Terence
Macias, William
ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S652 - S652
[6] EFFICACY AND SAFETY OF BARICITINIB VERSUS PLACEBO AND ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: SUMMARY RESULTS FROM THE 52-WEEK PHASE 3 RA-BEAM STUDY
Taylor, Peter C.
Krogulec, Marek
Dudek, Anna
Dudler, Jean
Drescher, Edit
Cseuz, Regina
Kausiene, Rasa
Andersone, Daina
Unikiene, Dalia
Sanchez Burson, Juan
Blanco Alonso, Ricardo
Dvorak, Zdenek
Ghizdavescu, Andrei
Irto, Ildiko
Larsson, Esbjorn
Bello, Natalia
Barry, Jane
Durand, Frederick
Holzkaemper, Thorsten
Otawa, Susan
de Bono, Stephanie
Keystone, Edward C.
Rubbert-Roth, Andrea
Combe, Bernard
De La Torre, Inmaculada
RHEUMATOLOGY, 2017, 56 : 26 - 27
[7] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52 Week Results from a Phase 3 Study
Mease, Philip J.
Okada, Masato
Kishimoto, Mitsumasa
Shuler, Catherine L.
Carlier, Hilde
Lin, Chen-Yen
Mou, Jiani
Moriarty, Susan R.
Lee, Chin H.
Gladman, Dafna D.
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[8] BARICITINIB, METHOTREXATE, OR BARICITINIB PLUS METHOTREXATE IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAD RECEIVED LIMITED OR NO TREATMENT WITH DMARDS: EFFICACY AND SAFETY RESULTS FROM THE 52-WEEK PHASE 3 RA-BEGIN STUDY
Durez, Patrick
Walker, David
Geusens, Piet
Van den Bosch, Filip
Shaikh, Saeed
Roccatello, Dario
Tahir, Hasan
Zamani, Omid
Stoykov, Ivaylo
Otawa, Susan
Rogai, Veronica
Larsson, Esbjorn
Holzkaemper, Thorsten
Arthanari, Subhashini
Pum, Georg
Leage, Soyi Liu
Gjertsson, Inger
Puttini, Piercarlo Sarzi
Kekow, Joern
De La Torre, Inmaculada
RHEUMATOLOGY, 2017, 56 : 134 - 135
[9] EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CSDMARDS: SUMMARY RESULTS FROM THE 24-WEEK PHASE III RA-BUILD STUDY
Emery, Paul
Krogulec, Marek
Blanco Alonso, Ricardo
Rossini, Maurizio
Raeman, Frank
Walker, David
Ghizdavescu, Andrei Petru
Irto, Ildiko
Luz Rentero, Maria
Casillas, Marta
de la Torre, Inmaculada
Dougados, Maxime
RHEUMATOLOGY, 2016, 55 : 60 - 60
[10] Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in MTX-IR Patients with Rheumatoid Arthritis
Tanaka, Yoshiya
Takeuchi, Tsutomu
Yamanaka, Hisashi
Nanki, Toshihiro
Umehara, Hisanori
Yasuda, Nobuyuki
Tago, Fumitoshi
Kitahara, Yasumi
Kawakubo, Makoto
Torii, Kentaro
Hojo, Seiichiro
Kawano, Tetsu
Imai, Toshio
ARTHRITIS & RHEUMATOLOGY, 2019, 71

← 1 2 3 4 5 →